Skip to content

US · GILD · DRUG MANUFACTURERS - GENERAL

Gilead Sciences, Inc. (GILD) intrinsic value and stock valuation

$166.43as of 2026-11-21 · Mkt cap 165.39B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Gilead Sciences, Inc. DCF and intrinsic value

InvestorsCraft values GILD with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from GILD’s statements →

Gilead Sciences, Inc. Graham Number

Graham Number: $52.90d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - General Foster City, CA 94404 gilead.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$29.4B+3.6% 5y CAGRd
20112025
Net income
$8.51B+133.3% 5y CAGRd
20112025
Free cash flow
$9.46B+4.7% 5y CAGRd
20112025
Total equity
$22.6B+4.4% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$29.4B$28.8B$27.1B$27.3B$27.3B
Operating income$11.7B$1.66B$7.61B$7.33B$9.92B
Net income$8.51B$480M$5.67B$4.59B$6.23B
EPSd$6.78M$382.5K$4.5M$3.64M$4.93M
Operating cash flow$10B$10.8B$8.01B$9.07B$11.4B
Capital expenditure-$-563M-$-523M-$-585M-$-728M-$-579M
Free cash flow$9.46B$10.3B$7.42B$8.34B$10.8B
Total assets$59B$59B$62.1B$63.2B$68B
Total debt$24.9B$26.7B$25B$25.2B$26.7B
Net debt$17.4B$16.7B$18.9B$19.8B$21.4B
Total equity$22.6B$19.2B$22.7B$21.2B$21.1B
Cash and short-term investments$9.61B$11.6B$7.26B$6.39B$6.52B
Income statement
20252024202320222021
Revenue$29.4B$28.8B$27.1B$27.3B$27.3B
Cost of revenue$6.23B$6.25B$6.5B$5.66B$6.6B
Gross profit$23.2B$22.5B$20.6B$21.6B$20.7B
Research and development expenses$5.8B$5.91B$5.72B$4.98B$4.6B
Selling, general and administrative expenses$5.71B$6.09B$6.09B$5.67B$5.25B
Other expenses$0.00$8.84B$1.21B$3.64B$939M
Operating expenses$11.5B$20.8B$13B$14.3B$10.8B
Cost and expenses$17.7B$27.1B$19.5B$20B$17.4B
Interest income$349M$281M$376M$106M$0.00
Interest expense$1.02B$977M$944M$935M$1B
Depreciation and amortization$2.76B$2.77B$2.69B$2.1B$2.05B
Ebitda$13.6B$4.43B$10.5B$8.85B$11.3B
Operating income$11.7B$1.66B$7.61B$7.33B$9.92B
Total other income/expenses, net-$-1.91B-$-972M-$-746M-$-1.52B-$-1.64B
Income before tax$9.8B$690M$6.86B$5.81B$8.28B
Income tax expense$1.29B$211M$1.25B$1.25B$2.08B
Net income$8.51B$480M$5.67B$4.59B$6.23B
Weighted average shares outstanding$1.24B$1.25B$1.25B$1.26B$1.26B
Weighted average diluted shares outstanding$1.26B$1.26B$1.26B$1.26B$1.26B
Balance sheet
20252024202320222021
Cash and short-term investments$9.61B$11.6B$7.26B$6.39B$6.52B
Net receivables$4.91B$4.42B$4.66B$4.78B$4.49B
Inventory$1.77B$1.71B$1.79B$1.51B$1.62B
Total current assets$18.3B$19.2B$16.1B$14.4B$14.8B
Property, plant and equipment, net$5.61B$5.41B$5.32B$5.48B$5.12B
Goodwill and intangible assets$25.3B$28.3B$34.8B$37.2B$41.8B
Long-term investments$2.97B$0.00$1.16B$1.25B$1.31B
Total non-current assets$40.7B$39.8B$46B$48.7B$53.2B
Total assets$59B$59B$62.1B$63.2B$68B
Accounts payable$715M$833M$550M$905M$705M
Short-term debt$2.81B$1.82B$1.8B$2.27B$1.52B
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$11.8B$12B$11.3B$11.2B$11.6B
Long-term debt$22.1B$24.9B$23.2B$23B$25.2B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$24.6B$27.7B$28.1B$30.7B$35.3B
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$36.4B$39.7B$39.4B$42B$46.9B
Common stock$1M$1M$1M$1M$1M
Retained earnings$13.7B$11.5B$16.3B$15.7B$16.3B
Accumulated other comprehensive income (loss)$39M$132M$28M$2M$83M
Total equity$22.6B$19.2B$22.7B$21.2B$21.1B
Total investments$5.02B$1.58B$2.34B$2.22B$2.49B
Total debt$24.9B$26.7B$25B$25.2B$26.7B
Net debt$17.4B$16.7B$18.9B$19.8B$21.4B
Cash flow statement
20252024202320222021
Net income$8.51B$480M$5.67B$4.59B$6.2B
Depreciation and amortization$2.76B$2.77B$2.69B$2.1B$2.05B
Stock-based compensation$894M$835M$766M$644M$635M
Change in working capital-$-3.95B-$-880M-$-2.3B-$-1.76B$489M
Accounts receivable-$-367M$139M$157M-$-406M$313M
Inventory-$-1.04B-$-426M-$-842M-$-310M$11M
Accounts payable-$-132M$290M-$-347M$226M-$-118M
Net cash provided by operating activities$10B$10.8B$8.01B$9.07B$11.4B
Investments in property, plant and equipment-$-563M-$-523M-$-585M-$-728M-$-579M
Acquisitions, net-$-1.07B-$-4.84B-$-1.15B-$-1.8B-$-1.58B
Net cash used for investing activities-$-4.79B-$-3.45B-$-2.27B-$-2.47B-$-3.13B
Common stock issued$408M$422M$232M$309M$169M
Common stock repurchased-$-1.92B-$-1.15B-$-1B-$-1.4B-$-546M
Dividends paid-$-4B-$-3.92B-$-3.81B-$-3.71B-$-3.61B
Net cash used for financing activities-$-7.75B-$-3.43B-$-5.13B-$-6.47B-$-8.88B
Net change in cash-$-2.43B$3.91B$673M$74M-$-659M
Cash at end of period$7.56B$9.99B$6.09B$5.41B$5.34B
Operating cash flow$10B$10.8B$8.01B$9.07B$11.4B
Capital expenditure-$-563M-$-523M-$-585M-$-728M-$-579M
Free cash flow$9.46B$10.3B$7.42B$8.34B$10.8B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Gilead Sciences, Inc.

        Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

        CEO
        Daniel O'Day
        Employees
        17K
        Beta
        0.34

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Gilead Sciences, Inc. (GILD)?

        Gilead Sciences, Inc. (GILD) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is GILD undervalued?

        GILD trades at a price of $166.43 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.